CCO HER2 Positive Breast Cancer 2021 Slides 3 (1)

HER2-Positive Breast Cancer: A Guide Through an
Evolving Treatment Landscape
This program is supported by educational grants from Genentech,
a member of the Roche Group, and Puma Biotechnology, Inc.

Jame Abraham, MD
Chairman
Department of Hematology and Medical Oncology
Taussig Cancer Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland Clinic
Cleveland, Ohio
Expert Guidance on the Evolving Therapeutic
Landscape for HER2-Positive Early-Stage Breast
Cancer

Faculty Disclosures
Jame Abraham, MD, has no relevant financial relationships to disclose.

About These Slides
Please feel free to use, update, and share some or all of these slides in
your noncommercial presentations to colleagues or patients
When using our slides, please retain the source attribution:
These slides may not be published, posted online, or used in
commercial presentations without permission. Please contact
permissi[email protected] for details
Slide credit: clinicaloptions.com

Agenda
Adjuvant therapy in HER-2 positive early breast cancer
‒Low risk HER-2 positive
‒High Risk HER-2 positive
Extended adjuvant
Neo-adjuvant
Post neo-adjuvant